We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Mylan (MYL) to Report Q4 Earnings: What's in the Offing?
Read MoreHide Full Article
Mylan N.V. is expected to beat on earnings in fourth-quarter 2019.
The company’s performance has been pretty good so far, with an earnings beat in three of the trailing four quarters and a miss in the remaining quarter. Mylan reported a four-quarter beat of 3.15%, on average, over the said timeframe. In the last reported quarter, the company’s earnings beat estimates by 2.63%.
Our proven model predicts an earnings beat for Mylan this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: Mylan has an Earnings ESP of +0.11%.
Zacks Rank: The company has a Zacks Rank #3.
Factors to Consider
The company posts results in three segments on a geographic basis — North America, Europe and the Rest of the World.
North America reported 8% year-over-year growth in the third quarter owing to solid new product sales, a trend that most likely continued in the fourth quarter. New product sales are being primarily driven by the robust performance of Yupleri and Wixela Inhub, the generic of Advair Diskus. Yupleri gained momentum in the third quarter and the same is expected to continue in the fourth quarter. The growth in demand for Fulphila (biosimilar to Neulasta) should boost sales too.
In December, Mylan launched Ogivri, a biosimilar to Roche’s Herceptin (trastuzumab), in the United States. Ogivri is approved for all indications of Herceptin, including the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma).
Net sales in Europe might have benefited from new products, including Hulio, and higher volumes of existing products in the fourth quarter.
The Rest of the World segment’s fourth-quarter net sales are likely to have benefited from new product sales in Australia and emerging markets, and higher volumes of existing products primarily driven by products sold in emerging markets.
Key Anticipated Updates
Investors will be keen on pipeline updates as well. The phase III study on bevacizumab, a biosimilar to Avastin in collaboration with Biocon, met the necessary endpoint criteria for the treatment of non-small cell lung cancer. Regulatory submissions were planned shortly and we expect management to throw light on the same.
Concurrent with the second-quarter results, Mylan announced a merger agreement with Upjohn, Pfizer's (PFE - Free Report) off-patent branded and generic established medicines business (includes Lipitor, Celebrex and Viagra), to create a new global pharmaceutical company.
In November 2019, Mylan and Pfizer announced the name of the new company to be Viatris. Subsequently, the companies announced two future Viatris board members. The merger will be completed by mid-2020. We expect management to throw more light on the progress made so far in this deal.
Share Price Performance
Mylan’s stock has lost 31.8% in the past year against the industry’s growth of 1.5%.
Other Stocks to Consider
Here are a few other companies worth considering, as per our model these have the right mix of elements to beat on earnings this reporting cycle.
Immunomedics, Inc. has an Earnings ESP of +3.37% and a Zacks Rank #2.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
Image: Bigstock
Mylan (MYL) to Report Q4 Earnings: What's in the Offing?
Mylan N.V. is expected to beat on earnings in fourth-quarter 2019.
The company’s performance has been pretty good so far, with an earnings beat in three of the trailing four quarters and a miss in the remaining quarter. Mylan reported a four-quarter beat of 3.15%, on average, over the said timeframe. In the last reported quarter, the company’s earnings beat estimates by 2.63%.
Mylan N.V. Price, Consensus and EPS Surprise
Mylan N.V. price-consensus-eps-surprise-chart | Mylan N.V. Quote
Why a Likely Earnings Beat
Our proven model predicts an earnings beat for Mylan this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: Mylan has an Earnings ESP of +0.11%.
Zacks Rank: The company has a Zacks Rank #3.
Factors to Consider
The company posts results in three segments on a geographic basis — North America, Europe and the Rest of the World.
North America reported 8% year-over-year growth in the third quarter owing to solid new product sales, a trend that most likely continued in the fourth quarter. New product sales are being primarily driven by the robust performance of Yupleri and Wixela Inhub, the generic of Advair Diskus. Yupleri gained momentum in the third quarter and the same is expected to continue in the fourth quarter. The growth in demand for Fulphila (biosimilar to Neulasta) should boost sales too.
In December, Mylan launched Ogivri, a biosimilar to Roche’s Herceptin (trastuzumab), in the United States. Ogivri is approved for all indications of Herceptin, including the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma).
Net sales in Europe might have benefited from new products, including Hulio, and higher volumes of existing products in the fourth quarter.
The Rest of the World segment’s fourth-quarter net sales are likely to have benefited from new product sales in Australia and emerging markets, and higher volumes of existing products primarily driven by products sold in emerging markets.
Key Anticipated Updates
Investors will be keen on pipeline updates as well. The phase III study on bevacizumab, a biosimilar to Avastin in collaboration with Biocon, met the necessary endpoint criteria for the treatment of non-small cell lung cancer. Regulatory submissions were planned shortly and we expect management to throw light on the same.
Concurrent with the second-quarter results, Mylan announced a merger agreement with Upjohn, Pfizer's (PFE - Free Report) off-patent branded and generic established medicines business (includes Lipitor, Celebrex and Viagra), to create a new global pharmaceutical company.
In November 2019, Mylan and Pfizer announced the name of the new company to be Viatris. Subsequently, the companies announced two future Viatris board members. The merger will be completed by mid-2020. We expect management to throw more light on the progress made so far in this deal.
Share Price Performance
Mylan’s stock has lost 31.8% in the past year against the industry’s growth of 1.5%.
Other Stocks to Consider
Here are a few other companies worth considering, as per our model these have the right mix of elements to beat on earnings this reporting cycle.
Clovis Oncology, Inc. has an Earnings ESP of +0.81% and a Zacks Rank #2. It is scheduled to release earnings on Feb 24. You can see the complete list of today’s Zacks #1 Rank stocks here.
Immunomedics, Inc. has an Earnings ESP of +3.37% and a Zacks Rank #2.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>